Key Takeaways
- Define storage requirements based on the type of material and its intended use.
- Check temperature control and monitoring throughout storage and transport.
- Confirm that chain-of-custody records support accurate tracking and retrieval.
- Review emergency plans for equipment failures, power outages, and temperature changes.
- Examine quality agreements, audit records, and regulatory responsibilities.
- Consider logistics, transport access, and future program growth when choosing a provider.
For cell therapy developers, stored material is rarely replaceable. A patient’s apheresis collection, a master cell bank, or a batch of engineered cells may represent months of work and, in some cases, the only material available for a given patient or program. When that material moves to an outside storage facility, choosing a partner becomes as much a quality decision as a logistics one.
Specialized providers such as CellSecure Bio, which offers cryostorage, cell bank storage, and device and reagent validation for cell therapy programs, are among the options teams consider. Whichever provider is under review, the evaluation tends to come down to the same questions about temperature, traceability, resilience, and quality oversight.
Start With the Material, Not the Facility
The right storage conditions depend on what is being stored and how it will be used. Research samples, clinical trial material, patient-specific therapies, and cell banks can carry different requirements for temperature, container format, retention period, and retrieval speed. Documenting these needs before comparing providers keeps the conversation focused on fit rather than on a facility’s general capabilities.
Temperature is a central technical question. A 2020 review in Frontiers in Medicine notes that cryopreserved cells intended for long-term storage should be kept below about −130°C, that −80°C is not considered adequate for stable recovery, and that freezing, storage, transport, and thawing form a linked chain from source material to patient. A storage partner should be able to demonstrate how it maintains the required range throughout the entire chain, including during shipments and internal transfers.
Ask How Chain of Custody Is Documented
Freezer space is only part of the service. Teams should ask how material is received, labeled, logged, accessed, retrieved, and released, and who signs off at each step. Useful questions include:
- How is each container identified and tracked to a specific storage location?
- Who can access storage areas and inventory records, and how is that access logged?
- What documentation accompanies material at intake and at release?
- How are discrepancies investigated and reported to the client?
Labeling deserves its own attention. Labels and barcodes must remain legible and attached at cryogenic temperatures, and inventory systems should enable quick retrieval of a single container without exposing neighboring samples to unnecessary warming.
For clinical programs, electronic records and monitoring data should be maintained to support the sponsor’s quality system and regulatory obligations.
Test the Contingency Plan
Equipment fails, power goes out, and liquid nitrogen deliveries can be delayed. A credible provider should be able to explain what happens in each case. Ask about continuous temperature monitoring, alarm escalation and response outside business hours, backup units ready to receive transferred material, redundant power, and supply arrangements for liquid nitrogen. Where possible, request records from past alarm events or drills rather than relying on descriptions alone. It is also worth asking how quickly the client is notified when an excursion occurs, and what information that notification includes.
Review the Quality Agreement Carefully
Storage practices feed into a sponsor’s broader quality and regulatory program. The FDA’s guidance on developing cellular and gene therapy products is one reference point for the chemistry, manufacturing, and controls expectations that storage and handling records help support.
The quality agreement should spell out responsibilities for deviations, investigations, change control, audits, and client notification. Teams should plan to audit the facility, or review a recent audit report, before any material is transferred. Compliance claims should be confirmed against documentation rather than accepted from marketing materials.
Consider Logistics and Program Growth
Location and transport access affect how quickly material can be retrieved and how many handoffs it passes through along the way. Teams should also plan ahead: a provider that suits an early research program may later need to handle larger volumes, clinical material, or additional services.
Some developers prefer a partner that also offers process development or validation support, which can reduce the number of vendors they need to coordinate with. Others keep those functions separate. Either approach can work, provided responsibilities are clearly defined in writing.
Bringing It Together
Choosing a storage partner is ultimately about protecting material that cannot easily be replaced. By defining material requirements first, examining chain-of-custody and contingency practices in detail, and confirming quality commitments in writing, cell therapy teams can compare providers on evidence and select one that fits the specific risks of their program.
